<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/84880128654</prism:url><dc:identifier>SCOPUS_ID:84880128654</dc:identifier><eid>2-s2.0-84880128654</eid><pubmed-id>23771370</pubmed-id><prism:doi>10.4103/0973-1482.113379</prism:doi><dc:title>Efficacy of tyrosine kinase inhibitors in routine clinical practice: Epidermal growth factor mutations and their implications</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>4</citedby-count><prism:publicationName>Journal of Cancer Research and Therapeutics</prism:publicationName><source-id>145443</source-id><prism:issn>09731482 19984138</prism:issn><prism:volume>9</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:startingPage>261</prism:startingPage><prism:endingPage>266</prism:endingPage><prism:pageRange>261-266</prism:pageRange><prism:coverDate>2013-04-01</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="36992456700"><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovcaricek</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovcaricek</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36992456700</author-url><affiliation id="112789909" href="https://api.elsevier.com/content/affiliation/affiliation_id/112789909"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng">
<ce:para>Background: Activating mutations in the epidermal growth factor (EGFR) gene confer sensitivity to the tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC). TKI treatment efficacy and EGFR mutation implications were evaluated in clinically selected advanced NSCLC patients treated with TKIs in routine clinical practice. Materials and Methods: A retrospective chart review for clinicopathological characteristics and mutation status (EGFR, KRAS) analysis of 40 consecutive patients treated with TKIs between 2005 and 2010 was performed. Statistical Analysis Used: PFS and OS were estimated by the Kaplan-Meier method, the log-rank test was used to test for differences. The strength of the associations between the EGFR mutation status and clinicopathological characteristics were tested with the Mann-Whitney U-test or the Kruskal-Wallis H-test. Results: The prevalence of EGFR mutations was 45% with a predominance of deletion mutations in exon 19 (55.5%). Significant correlations between gender, histology, and EGFR mutations were observed. Median progression-free survival (mPFS) for the entire group of patients was 8.7 months and median overall survival (mOS) was not yet reached. Patients with EGFR mutant tumors derived significantly higher benefit from TKI therapy compared to patients with mutation-negative disease; with mPFS of 22.0 vs. 3.2 months (HR: 3.9, 95% CI 1.56-9.89) and with a trend towards better OS (probability of survival at 12 months 82.0 vs. 63.0%, P = 0.080). Conclusion: We demonstrated that screening for EGFR mutations is reliable in a routine clinical setting and might allow for a better selection of NSCLC patients for anti-EGFR TKI therapy.</ce:para>
</abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/84880128654" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84880128654&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=84880128654&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"><affilname>Bolnišnica Golnik</affilname><affiliation-city>Golnik</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="112789909" href="https://api.elsevier.com/content/affiliation/affiliation_id/112789909"><affilname>University Clinic Maribor</affilname><affiliation-city>Maribor</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="36992456700"><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovcaricek</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovcaricek</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36992456700</author-url><affiliation id="112789909" href="https://api.elsevier.com/content/affiliation/affiliation_id/112789909"/></author><author seq="2" auid="7004393140"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004393140</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="3" auid="7003295818"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name><preferred-name><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7003295818</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="4" auid="36992707400"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name><preferred-name><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36992707400</author-url><affiliation id="60078312" href="https://api.elsevier.com/content/affiliation/affiliation_id/60078312"/></author><author seq="5" auid="55883901600"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55883901600</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>Epidermal growth factor mutations</author-keyword><author-keyword>Non-small cell lung cancer</author-keyword><author-keyword>Routine clinical practice</author-keyword><author-keyword>Tyrosine kinase inhibitors</author-keyword></authkeywords><idxterms/><subject-areas><subject-area code="2730" abbrev="MEDI">Oncology</subject-area><subject-area code="2741" abbrev="MEDI">Radiology, Nuclear Medicine and Imaging</subject-area></subject-areas><item xmlns=""><ait:process-info><ait:date-delivered day="09" month="03" timestamp="2014-03-09T03:05:13.000013+00:00" year="2014"/><ait:date-sort day="01" month="04" year="2013"/><ait:status stage="S300" state="update" type="core"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2014 Elsevier B.V., All rights reserved.</copyright><copyright type="Medline Descriptors">MEDLINE® is the source for the MeSH terms of this document.</copyright><itemidlist>
<ce:doi>10.4103/0973-1482.113379</ce:doi>
<itemid idtype="PUI">369310438</itemid>
<itemid idtype="EMBASE">2013439046</itemid>
<itemid idtype="NURSNG">2013195454</itemid>
<itemid idtype="MEDL">23771370</itemid>
<itemid idtype="SCP">84880128654</itemid>
<itemid idtype="SGR">84880128654</itemid>
</itemidlist><history>
<date-created day="18" month="07" year="2013"/>
</history><dbcollection>EMBASE</dbcollection><dbcollection>NURSNG</dbcollection><dbcollection>MEDL</dbcollection><dbcollection>Scopusbase</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords>
<author-keyword>Epidermal growth factor mutations</author-keyword>
<author-keyword>Non-small cell lung cancer</author-keyword>
<author-keyword>Routine clinical practice</author-keyword>
<author-keyword>Tyrosine kinase inhibitors</author-keyword>
</author-keywords></citation-info><citation-title><titletext original="y" xml:lang="eng" language="English">Efficacy of tyrosine kinase inhibitors in routine clinical practice: Epidermal growth factor mutations and their implications</titletext></citation-title><author-group><author auid="36992456700" seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Ovcaricek T.</ce:indexed-name><ce:surname>Ovcaricek</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name>
<ce:initials>T.</ce:initials>
<ce:indexed-name>Ovcaricek T.</ce:indexed-name>
<ce:surname>Ovcaricek</ce:surname>
<ce:given-name>Tanja</ce:given-name>
</preferred-name></author><affiliation afid="112789909" country="svn" dptid="113729841"><organization>Department of Pulmonary Medicine</organization><organization>University Clinic Maribor</organization><city-group>Maribor</city-group><country>Slovenia</country></affiliation></author-group><author-group><author auid="7004393140" seq="2"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name>
<ce:initials>T.</ce:initials>
<ce:indexed-name>Cufer T.</ce:indexed-name>
<ce:surname>Cufer</ce:surname>
<ce:given-name>Tanja</ce:given-name>
</preferred-name></author><author auid="7003295818" seq="3"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name><preferred-name>
<ce:initials>I.</ce:initials>
<ce:indexed-name>Kern I.</ce:indexed-name>
<ce:surname>Kern</ce:surname>
<ce:given-name>Izidor</ce:given-name>
</preferred-name></author><author auid="36992707400" seq="4"><ce:initials>E.</ce:initials><ce:indexed-name>Sodja E.</ce:indexed-name><ce:surname>Sodja</ce:surname><ce:given-name>Eva</ce:given-name><preferred-name>
<ce:initials>E.</ce:initials>
<ce:indexed-name>Sodja E.</ce:indexed-name>
<ce:surname>Sodja</ce:surname>
<ce:given-name>Eva</ce:given-name>
</preferred-name></author><affiliation afid="60078312" country="svn" dptid="107870123"><organization>Department of Medical Oncology</organization><organization>University Clinic Golnik</organization><city-group>Golnik</city-group><country>Slovenia</country></affiliation></author-group><author-group><author auid="55883901600" seq="5"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name>
<ce:initials>A.</ce:initials>
<ce:indexed-name>Sadikov A.</ce:indexed-name>
<ce:surname>Sadikov</ce:surname>
<ce:given-name>Aleksander</ce:given-name>
</preferred-name></author><affiliation afid="60031106" country="svn" dptid="104580788"><organization>Department of Computer and Information Science</organization><organization>University of Ljubljana</organization><city-group>Ljubljana</city-group><country>Slovenia</country></affiliation></author-group><correspondence><person>
<ce:initials>T.</ce:initials>
<ce:indexed-name>Ovcaricek T.</ce:indexed-name>
<ce:degrees>Dr.</ce:degrees>
<ce:surname>Ovcaricek</ce:surname>
</person><affiliation country="svn"><organization>Oncology Institute</organization><address-part>Ljubljana, Zaloška cesta 2</address-part><city-group>1000 Ljubljana</city-group><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng">
<ce:para>Background: Activating mutations in the epidermal growth factor (EGFR) gene confer sensitivity to the tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC). TKI treatment efficacy and EGFR mutation implications were evaluated in clinically selected advanced NSCLC patients treated with TKIs in routine clinical practice. Materials and Methods: A retrospective chart review for clinicopathological characteristics and mutation status (EGFR, KRAS) analysis of 40 consecutive patients treated with TKIs between 2005 and 2010 was performed. Statistical Analysis Used: PFS and OS were estimated by the Kaplan-Meier method, the log-rank test was used to test for differences. The strength of the associations between the EGFR mutation status and clinicopathological characteristics were tested with the Mann-Whitney U-test or the Kruskal-Wallis H-test. Results: The prevalence of EGFR mutations was 45% with a predominance of deletion mutations in exon 19 (55.5%). Significant correlations between gender, histology, and EGFR mutations were observed. Median progression-free survival (mPFS) for the entire group of patients was 8.7 months and median overall survival (mOS) was not yet reached. Patients with EGFR mutant tumors derived significantly higher benefit from TKI therapy compared to patients with mutation-negative disease; with mPFS of 22.0 vs. 3.2 months (HR: 3.9, 95% CI 1.56-9.89) and with a trend towards better OS (probability of survival at 12 months 82.0 vs. 63.0%, P = 0.080). Conclusion: We demonstrated that screening for EGFR mutations is reliable in a routine clinical setting and might allow for a better selection of NSCLC patients for anti-EGFR TKI therapy.</ce:para>
</abstract></abstracts><source country="ind" srcid="145443" type="j"><sourcetitle>Journal of Cancer Research and Therapeutics</sourcetitle><sourcetitle-abbrev>J. Cancer Res. Ther.</sourcetitle-abbrev><issn type="print">09731482</issn><issn type="electronic">19984138</issn><volisspag>
<voliss issue="2" volume="9"/>
<pagerange first="261" last="266"/>
</volisspag><publicationyear first="2013"/><publicationdate>
<year>2013</year>
<month>04</month>
<day>01</day>
<date-text xfab-added="true">1 April 2013</date-text></publicationdate></source><enhancement><classificationgroup>
<classifications type="ASJC">
<classification>2730</classification>
<classification>2741</classification>
</classifications><classifications type="SUBJABBR"><classification>MEDI</classification></classifications>
<classifications type="EMCLASS">
<classification> <classification-code>15</classification-code> <classification-description>Chest Diseases, Thoracic Surgery and Tuberculosis</classification-description> </classification>
<classification> <classification-code>16</classification-code> <classification-description>Cancer</classification-description> </classification>
<classification> <classification-code>37</classification-code> <classification-description>Drug Literature Index</classification-description> </classification>
</classifications>
</classificationgroup><chemicalgroup>
<chemicals source="esbd">
<chemical>
<chemical-name>epidermal growth factor</chemical-name>
<cas-registry-number>62229-50-9</cas-registry-number>
</chemical>
</chemicals>
<chemicals source="nlm">
<chemical>
<chemical-name>EGFR protein, human</chemical-name>
<cas-registry-number>2.7.10.1</cas-registry-number>
</chemical>
<chemical>
<chemical-name>Protein Kinase Inhibitors</chemical-name>
<cas-registry-number>0</cas-registry-number>
</chemical>
<chemical>
<chemical-name>Protein-Tyrosine Kinases</chemical-name>
<cas-registry-number>2.7.10.1</cas-registry-number>
</chemical>
<chemical>
<chemical-name>Receptor, Epidermal Growth Factor</chemical-name>
<cas-registry-number>2.7.10.1</cas-registry-number>
</chemical>
</chemicals>
</chemicalgroup></enhancement></head><tail><bibliography refcount="22">
<reference id="1">
<ref-info>
<ref-title>
<ref-titletext>Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0036843105</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>G.V.</ce:initials>
<ce:indexed-name>Scagliotti G.V.</ce:indexed-name>
<ce:surname>Scagliotti</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:indexed-name>De Marinis F.</ce:indexed-name>
<ce:surname>De Marinis</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Rinaldi M.</ce:indexed-name>
<ce:surname>Rinaldi</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Crino L.</ce:indexed-name>
<ce:surname>Crinò</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Gridelli C.</ce:indexed-name>
<ce:surname>Gridelli</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Ricci S.</ce:indexed-name>
<ce:surname>Ricci</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<ref-volisspag>
<voliss volume="20"/>
<pagerange first="4285" last="4291"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-91</ref-fulltext>
</reference>
<reference id="2">
<ref-info>
<ref-title>
<ref-titletext>Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0037050352</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.H.</ce:initials>
<ce:indexed-name>Schiller J.H.</ce:indexed-name>
<ce:surname>Schiller</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:indexed-name>Harrington D.</ce:indexed-name>
<ce:surname>Harrington</ce:surname>
</author>
<author seq="3">
<ce:initials>C.P.</ce:initials>
<ce:indexed-name>Belani C.P.</ce:indexed-name>
<ce:surname>Belani</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Langer C.</ce:indexed-name>
<ce:surname>Langer</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Sandler A.</ce:indexed-name>
<ce:surname>Sandler</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Krook J.</ce:indexed-name>
<ce:surname>Krook</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<ref-volisspag>
<voliss volume="346"/>
<pagerange first="92" last="98"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J. Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer. N Engl J Med 2002;346:92-8</ref-fulltext>
</reference>
<reference id="3">
<ref-info>
<ref-title>
<ref-titletext>The EGF receptor family as targets for cancer therapy</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0034722889</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Mendelsohn J.</ce:indexed-name>
<ce:surname>Mendelsohn</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Baselga J.</ce:indexed-name>
<ce:surname>Baselga</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<ref-volisspag>
<voliss volume="19"/>
<pagerange first="6550" last="6556"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-6</ref-fulltext>
</reference>
<reference id="4">
<ref-info>
<ref-title>
<ref-titletext>Erlotinib in previously treated non-small-cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">22044445517</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>F.A.</ce:initials>
<ce:indexed-name>Shepherd F.A.</ce:indexed-name>
<ce:surname>Shepherd</ce:surname>
</author>
<author seq="2">
<ce:initials>J.R.</ce:initials>
<ce:indexed-name>Pereira J.R.</ce:indexed-name>
<ce:surname>Pereira</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Ciuleanu T.</ce:indexed-name>
<ce:surname>Ciuleanu</ce:surname>
</author>
<author seq="4">
<ce:initials>E.H.</ce:initials>
<ce:indexed-name>Tan E.H.</ce:indexed-name>
<ce:surname>Tan</ce:surname>
</author>
<author seq="5">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Hirsch V.</ce:indexed-name>
<ce:surname>Hirsch</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Thongprassert S.</ce:indexed-name>
<ce:surname>Thongprassert</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-volisspag>
<voliss volume="353"/>
<pagerange first="123" last="132"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsch V, Thongprassert S. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32</ref-fulltext>
</reference>
<reference id="5">
<ref-info>
<ref-title>
<ref-titletext>Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo-controlled, multi-centre study (iressa survival evaluation in lung cancers)</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">27544503230</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:indexed-name>Thatcher N.</ce:indexed-name>
<ce:surname>Thatcher</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Chang A.</ce:indexed-name>
<ce:surname>Chang</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Parikh P.</ce:indexed-name>
<ce:surname>Parikh</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Rodrigues Pereira J.</ce:indexed-name>
<ce:surname>Rodrigues Pereira</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Ciuleanu T.</ce:indexed-name>
<ce:surname>Ciuleanu</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Von Pawel J.</ce:indexed-name>
<ce:surname>Von Pawel</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-volisspag>
<voliss volume="366"/>
<pagerange first="1527" last="1537"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo-controlled, multi-centre study (Iressa Survival Evaluation in Lung Cancers). Lancet 2005;366:1527-37</ref-fulltext>
</reference>
<reference id="6">
<ref-info>
<ref-title>
<ref-titletext>Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">20044364940</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:indexed-name>Shigematsu H.</ce:indexed-name>
<ce:surname>Shigematsu</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Lin L.</ce:indexed-name>
<ce:surname>Lin</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Takahashi T.</ce:indexed-name>
<ce:surname>Takahashi</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Nomura M.</ce:indexed-name>
<ce:surname>Nomura</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Suzuki M.</ce:indexed-name>
<ce:surname>Suzuki</ce:surname>
</author>
<author seq="6">
<ce:initials>I.</ce:initials>
<ce:indexed-name>Wistuba I.</ce:indexed-name>
<ce:surname>Wistuba</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Natl Cancer Inst</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-volisspag>
<voliss volume="97"/>
<pagerange first="339" last="346"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba I. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46</ref-fulltext>
</reference>
<reference id="7">
<ref-info>
<ref-title>
<ref-titletext>Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">10844231985</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Kosaka T.</ce:indexed-name>
<ce:surname>Kosaka</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:indexed-name>Yatabe Y.</ce:indexed-name>
<ce:surname>Yatabe</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:indexed-name>Endoh H.</ce:indexed-name>
<ce:surname>Endoh</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:indexed-name>Kuwano H.</ce:indexed-name>
<ce:surname>Kuwano</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Takahashi T.</ce:indexed-name>
<ce:surname>Takahashi</ce:surname>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Mitsudomi T.</ce:indexed-name>
<ce:surname>Mitsudomi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<ref-volisspag>
<voliss volume="64"/>
<pagerange first="8919" last="8923"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 2004;64:8919-23</ref-fulltext>
</reference>
<reference id="8">
<ref-info>
<ref-title>
<ref-titletext>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">2342471392</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:indexed-name>Lynch T.J.</ce:indexed-name>
<ce:surname>Lynch</ce:surname>
</author>
<author seq="2">
<ce:initials>D.W.</ce:initials>
<ce:indexed-name>Bell D.W.</ce:indexed-name>
<ce:surname>Bell</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Sordella R.</ce:indexed-name>
<ce:surname>Sordella</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Gurubhagavatula S.</ce:indexed-name>
<ce:surname>Gurubhagavatula</ce:surname>
</author>
<author seq="5">
<ce:initials>R.A.</ce:initials>
<ce:indexed-name>Okimoto R.A.</ce:indexed-name>
<ce:surname>Okimoto</ce:surname>
</author>
<author seq="6">
<ce:initials>B.W.</ce:initials>
<ce:indexed-name>Branningan B.W.</ce:indexed-name>
<ce:surname>Branningan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<ref-volisspag>
<voliss volume="350"/>
<pagerange first="2129" last="2139"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Branningan BW. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39</ref-fulltext>
</reference>
<reference id="9">
<ref-info>
<ref-title>
<ref-titletext>EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">2342624080</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.G.</ce:initials>
<ce:indexed-name>Paez J.G.</ce:indexed-name>
<ce:surname>Paez</ce:surname>
</author>
<author seq="2">
<ce:initials>P.A.</ce:initials>
<ce:indexed-name>Janne P.A.</ce:indexed-name>
<ce:surname>Janne</ce:surname>
</author>
<author seq="3">
<ce:initials>J.C.</ce:initials>
<ce:indexed-name>Lee J.C.</ce:indexed-name>
<ce:surname>Lee</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Tracy S.</ce:indexed-name>
<ce:surname>Tracy</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:indexed-name>Greuclih H.</ce:indexed-name>
<ce:surname>Greuclih</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Gabriel S.</ce:indexed-name>
<ce:surname>Gabriel</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<ref-volisspag>
<voliss volume="304"/>
<pagerange first="1497" last="1500"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Paez JG, Janne PA, Lee JC, Tracy S, Greuclih H, Gabriel S. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500</ref-fulltext>
</reference>
<reference id="10">
<ref-info>
<ref-title>
<ref-titletext>Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase iii interest trial</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77649222572</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.Y.</ce:initials>
<ce:indexed-name>Douillard J.Y.</ce:indexed-name>
<ce:surname>Douillard</ce:surname>
</author>
<author seq="2">
<ce:initials>F.A.</ce:initials>
<ce:indexed-name>Shepherd F.A.</ce:indexed-name>
<ce:surname>Shepherd</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Hirsh V.</ce:indexed-name>
<ce:surname>Hirsh</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Mok T.</ce:indexed-name>
<ce:surname>Mok</ce:surname>
</author>
<author seq="5">
<ce:initials>M.A.</ce:initials>
<ce:indexed-name>Socinski M.A.</ce:indexed-name>
<ce:surname>Socinski</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Gervais R.</ce:indexed-name>
<ce:surname>Gervais</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="28"/>
<pagerange first="744" last="5211"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST Trial. J Clin Oncol 2010;28:744-5211</ref-fulltext>
</reference>
<reference id="11">
<ref-info>
<ref-title>
<ref-titletext>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">69949162760</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>T.S.</ce:initials>
<ce:indexed-name>Mok T.S.</ce:indexed-name>
<ce:surname>Mok</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.L.</ce:initials>
<ce:indexed-name>Wu Y.L.</ce:indexed-name>
<ce:surname>Wu</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Thongpraserst S.</ce:indexed-name>
<ce:surname>Thongpraserst</ce:surname>
</author>
<author seq="4">
<ce:initials>C.H.</ce:initials>
<ce:indexed-name>Yang C.H.</ce:indexed-name>
<ce:surname>Yang</ce:surname>
</author>
<author seq="5">
<ce:initials>D.T.</ce:initials>
<ce:indexed-name>Chu D.T.</ce:indexed-name>
<ce:surname>Chu</ce:surname>
</author>
<author seq="6">
<ce:initials>N.</ce:initials>
<ce:indexed-name>Saijo N.</ce:indexed-name>
<ce:surname>Saijo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="361"/>
<pagerange first="947" last="957"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Mok TS, Wu YL, Thongpraserst S, Yang CH, Chu DT, Saijo N. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57</ref-fulltext>
</reference>
<reference id="12">
<ref-info>
<ref-title>
<ref-titletext>Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomized phase 3 trial</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">75249087060</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Mitsudomi T.</ce:indexed-name>
<ce:surname>Mitsudomi</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Morita S.</ce:indexed-name>
<ce:surname>Morita</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:indexed-name>Yatabe Y.</ce:indexed-name>
<ce:surname>Yatabe</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Negoro S.</ce:indexed-name>
<ce:surname>Negoro</ce:surname>
</author>
<author seq="5">
<ce:initials>I.</ce:initials>
<ce:indexed-name>Okamoto I.</ce:indexed-name>
<ce:surname>Okamoto</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Tsurutani J.</ce:indexed-name>
<ce:surname>Tsurutani</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="11"/>
<pagerange first="121" last="128"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J. Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomized phase 3 trial. Lancet Oncol 2010;11:121-8</ref-fulltext>
</reference>
<reference id="13">
<ref-info>
<ref-title>
<ref-titletext>Gefitinib for non-small-cell lung cancer with mutated EGFR</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77953930730</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Maemondo M.</ce:indexed-name>
<ce:surname>Maemondo</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Inoue A.</ce:indexed-name>
<ce:surname>Inoue</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:indexed-name>Kobayashi K.</ce:indexed-name>
<ce:surname>Kobayashi</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Sugawara S.</ce:indexed-name>
<ce:surname>Sugawara</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Oizumi S.</ce:indexed-name>
<ce:surname>Oizumi</ce:surname>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:indexed-name>Isobe H.</ce:indexed-name>
<ce:surname>Isobe</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="362"/>
<pagerange first="2380" last="2388"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H. Gefitinib for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8</ref-fulltext>
</reference>
<reference id="14">
<ref-info>
<ref-title>
<ref-titletext>Erlotinib versus chemotherapy in first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG 0802): A multi-centre, open-label, randomized, phase 3 study</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">79960889662</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Zhou C.</ce:indexed-name>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.L.</ce:initials>
<ce:indexed-name>Wu Y.L.</ce:indexed-name>
<ce:surname>Wu</ce:surname>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Chen G.</ce:indexed-name>
<ce:surname>Chen</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Feng J.</ce:indexed-name>
<ce:surname>Feng</ce:surname>
</author>
<author seq="5">
<ce:initials>X.Q.</ce:initials>
<ce:indexed-name>Liu X.Q.</ce:indexed-name>
<ce:surname>Liu</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Wang C.</ce:indexed-name>
<ce:surname>Wang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-volisspag>
<voliss volume="12"/>
<pagerange first="735" last="742"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C. Erlotinib versus chemotherapy in first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG 0802): A multi-centre, open-label, randomized, phase 3 study. Lancet Oncol 2011;12:735-42</ref-fulltext>
</reference>
<reference id="15">
<ref-info>
<ref-title>
<ref-titletext>Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced egfr mutation-positive non-small-cell lung cancer (eurtac): A multicentre, open-label, randomised phase 3 trial</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">84857502654</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Rosell R.</ce:indexed-name>
<ce:surname>Rosell</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Carcereny E.</ce:indexed-name>
<ce:surname>Carcereny</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Gervais R.</ce:indexed-name>
<ce:surname>Gervais</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Vergnenegre A.</ce:indexed-name>
<ce:surname>Vergnenegre</ce:surname>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:indexed-name>Massuti B.</ce:indexed-name>
<ce:surname>Massuti</ce:surname>
</author>
<author seq="6">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Felip E.</ce:indexed-name>
<ce:surname>Felip</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-volisspag>
<voliss volume="13"/>
<pagerange first="239" last="246"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012:13:239-46</ref-fulltext>
</reference>
<reference id="16">
<ref-info>
<ref-title>
<ref-titletext>Screening for epidermal growth factor mutations in lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">69949186250</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Rosell R.</ce:indexed-name>
<ce:surname>Rosell</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Moran T.</ce:indexed-name>
<ce:surname>Moran</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Queralt C.</ce:indexed-name>
<ce:surname>Queralt</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:indexed-name>Cardenal F.</ce:indexed-name>
<ce:surname>Cardenal</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Camps S.</ce:indexed-name>
<ce:surname>Camps</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Majem M.</ce:indexed-name>
<ce:surname>Majem</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="361"/>
<pagerange first="958" last="967"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Rosell R, Moran T, Queralt C, Cardenal F, Camps S, Majem M. Screening for epidermal growth factor mutations in lung cancer. N Engl J Med 2009;361:958-67</ref-fulltext>
</reference>
<reference id="17">
<ref-info>
<ref-title>
<ref-titletext>SATURN: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multi-centre, randomized, placebo-controlled phase 3 study</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">77953541527</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:indexed-name>Capuzzo F.</ce:indexed-name>
<ce:surname>Capuzzo</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Cuileanu T.</ce:indexed-name>
<ce:surname>Cuileanu</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Stelmakh L.</ce:indexed-name>
<ce:surname>Stelmakh</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Cicenas A.</ce:indexed-name>
<ce:surname>Cicenas</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Szczesna E.</ce:indexed-name>
<ce:surname>Szczesna</ce:surname>
</author>
<author seq="6">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Juhasz E.</ce:indexed-name>
<ce:surname>Juhasz</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="11"/>
<pagerange first="521" last="529"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Capuzzo F, Cuileanu T, Stelmakh L, Cicenas A, Szczesna E, Juhasz E. SATURN: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multi-centre, randomized, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9</ref-fulltext>
</reference>
<reference id="18">
<ref-info>
<ref-title>
<ref-titletext>Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: A meta-analysis</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">80052194689</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Bria E.</ce:indexed-name>
<ce:surname>Bria</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Milella M.</ce:indexed-name>
<ce:surname>Milella</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:indexed-name>Cuppone F.</ce:indexed-name>
<ce:surname>Cuppone</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Novello S.</ce:indexed-name>
<ce:surname>Novello</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Ceribelli A.</ce:indexed-name>
<ce:surname>Ceribelli</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Vaccaro V.</ce:indexed-name>
<ce:surname>Vaccaro</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Ann Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-volisspag>
<voliss volume="22"/>
<pagerange first="2277" last="2285"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Bria E, Milella M, Cuppone F, Novello S, Ceribelli A, Vaccaro V. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: A meta-analysis. Ann Oncol 2011;22:2277-85</ref-fulltext>
</reference>
<reference id="19">
<ref-info>
<ref-title>
<ref-titletext>Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">32944481596</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>G.J.</ce:initials>
<ce:indexed-name>Rieley G.J.</ce:indexed-name>
<ce:surname>Rieley</ce:surname>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:indexed-name>Pao W.</ce:indexed-name>
<ce:surname>Pao</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:indexed-name>Pham D.</ce:indexed-name>
<ce:surname>Pham</ce:surname>
</author>
<author seq="4">
<ce:initials>A.R.</ce:initials>
<ce:indexed-name>Li A.R.</ce:indexed-name>
<ce:surname>Li</ce:surname>
</author>
<author seq="5">
<ce:initials>N.</ce:initials>
<ce:indexed-name>Rizvi N.</ce:indexed-name>
<ce:surname>Rizvi</ce:surname>
</author>
<author seq="6">
<ce:initials>E.S.</ce:initials>
<ce:indexed-name>Venkatraman E.S.</ce:indexed-name>
<ce:surname>Venkatraman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-volisspag>
<voliss volume="12"/>
<pagerange first="839" last="844"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Rieley GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-44</ref-fulltext>
</reference>
<reference id="20">
<ref-info>
<ref-title>
<ref-titletext>Mutations in the epidermal growth factor receptor gene predicted prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">20244388126</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Mitsudomi T.</ce:indexed-name>
<ce:surname>Mitsudomi</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Kosaka T.</ce:indexed-name>
<ce:surname>Kosaka</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:indexed-name>Endoh H.</ce:indexed-name>
<ce:surname>Endoh</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:indexed-name>Horio Y.</ce:indexed-name>
<ce:surname>Horio</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Hida T.</ce:indexed-name>
<ce:surname>Hida</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Mori S.</ce:indexed-name>
<ce:surname>Mori</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-volisspag>
<voliss volume="23"/>
<pagerange first="2513" last="2520"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S. Mutations in the epidermal growth factor receptor gene predicted prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20</ref-fulltext>
</reference>
<reference id="21">
<ref-info>
<ref-title>
<ref-titletext>The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">19944430434</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Mascaux C.</ce:indexed-name>
<ce:surname>Mascaux</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:indexed-name>Iannino N.</ce:indexed-name>
<ce:surname>Iannino</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:indexed-name>Martin B.</ce:indexed-name>
<ce:surname>Martin</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Paesmans M.</ce:indexed-name>
<ce:surname>Paesmans</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Berghmans T.</ce:indexed-name>
<ce:surname>Berghmans</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Dusart M.</ce:indexed-name>
<ce:surname>Dusart</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br J Cancer</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-volisspag>
<voliss volume="92"/>
<pagerange first="131" last="139"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M. The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131-9</ref-fulltext>
</reference>
<reference id="22">
<ref-info>
<ref-title>
<ref-titletext>KRAS mutations in non-small cell lung cancer</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">65349107082</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>G.J.</ce:initials>
<ce:indexed-name>Riely G.J.</ce:indexed-name>
<ce:surname>Riely</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Marks J.</ce:indexed-name>
<ce:surname>Marks</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:indexed-name>Pao W.</ce:indexed-name>
<ce:surname>Pao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Proc Am Thorac Soc</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<ref-volisspag>
<voliss volume="6"/>
<pagerange first="201" last="205"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6:201-5</ref-fulltext>
</reference>
</bibliography></tail></bibrecord></item></abstracts-retrieval-response>